Lorigerlimab Shows Positive Interim Activity in Advanced Gynecologic Cancer Trial

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-26
Category: health
Source: Stock Titan (via MacroGenics)
Original source

MacroGenics, Inc. reported positive interim data from its ongoing Phase 2 LINNET study of lorigerlimab for advanced clear cell gynecologic cancer (CCGC). Presented at ESMO 2026, the results indicated a 25% confirmed response rate and a 44% disease control rate among evaluable CCGC patients. All observed responses were ongoing at the time of the data cutoff.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai